Isabel Kalofonos

Isabel Kalofonos joined Fulcrum in August 2024 from ImmunoGen, where she served as Senior Vice President and Chief Commercial Officer. While at ImmunoGen, she led commercial efforts globally for the launch of ELAHERE® (mirvetuximab soravtansine-gynx) for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Prior to ImmunoGen, she served as Senior Vice President and Global Head of the Prescription Business Unit at Galderma. During her tenure, she led the launch preparation for NEMLUVIO® (nemolizumab), a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, which included marketing, global market access, pricing, and health economics / outcomes research. She also led all commercial franchises of prescription products. Prior to Galderma, Isabel held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise. In this role she oversaw the global blockbuster launch of TAKHZYRO® (lanadelumab-flyo). Prior to the Takeda acquisition, Isabel held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals. Isabel holds a B.S. from Pontificia Universidad Javeriana and an M.B.A. from Babson College.